Skip to main content

Table 2 Characteristics of responding patients

From: Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

No.

Age

Diagnosis (WHO, FAB)

IPSS

Karyotype

Pretreatment

Total no. cycles

Response

Cytogenetic response

Cycles to response

Response duration/months

Dose reductions

Status

Survival

D05a

69

CMML II, CMML

Int-II

+8

Hydroxyurea

23

CR

CR

9

20

Aza 75%

Dead

26

D03a

73

RAEB II, RAEB

Int-II

Normal

None

18

CRdys

na

2

20

Aza 50%

Dead

23

D04a

72

sAML/MDS RAEB I

Int II

Complex (incl. −7)

None

6

CRdys

PR

1

9

none

Dead

11

D06a

64

CMML II, CMML

High

del(7q)

None

43

CRdys

CR

2

44

Aza 50%

Alive, ongoing

44

D17a

67

sAML/MDS, RAEB-T

High

del(20q)

None

19

CRdys

CR

9

16

Aza 50%, VPA reduction

Dead

30

F03a

77

AML de-novo

X

+21

Intensive chemotherapy

10

CRi

CR

8

13

VPA interruption

Dead

13

D14a

77

sAML/MDS, RAEB-T

High

Normal

None

24

CRdys

na

5

29

VPA discontinuation

Dead

36

D01a

69

sAML/MDS RAEB

High

Complex (incl −7)

None

4

PR

nd

1

19

VPA discontinuation

Lost to Follow up

19

D15a

74

RAEB I, RAEB

Int-II

−7, dup 1(q)

None

5

PR

PR

2

4

VPA discontinuation

dead

6

F02b

87

AML de-novo

X

Normal

LBH589

3

SD, marrow CR

na

na

2

VPA interruption

dead

2

F05b

59

sAML/MDS, RAEB-T

High

Complex (incl −7)

Intensive chemotherapy

3

SD, marrow CR

none

na

3

VPA interruption

allo-PBSCT - > CR, dead

13

D11b

74

t-AML

X

+6,+8

Epo

5

SD, marrow CR

none

na

8

Aza 75%

dead

9

D13b

72

sAML/MDS

X

Normal

None

6

SD, marrow PR (blast count: 34 → 8%)

na

na

8

none

dead

9

  1. na not applicable, nd not done
  2. aResponders
  3. bMarrow remissions only